Connecting the dots...Provectus Biopharmaceuticals: Hisun-Pfizer Pharmaceuticals Co., Ltd. & $PVCT?

May 15, 2013

Hisun-Pfizer Pharmaceuticals Co., Ltd. & $PVCT?

Putting one's ear to the ground, it appears there is belief among several (and notably different nodal groups/sub-networks of) shareholders that Zhejiang Hisun Pharmaceuticals and Pfizer's joint venture entity, Hisun-Pfizer Pharmaceuticals Co., Ltd. ("Hisun-Pfizer"), very shortly will extend an MOU to Provectus. Peter returns from India and will be in the office the week of May 20th, before he departs around the end of the week of May27th for Chicago and the ASCO Annual 2013 Meeting.

No comments:

Post a Comment

Disclaimer

This blog is neither intended to be nor is investment advice. The author of this blog (the "Author") is not a registered investment advisor. Under no circumstances should any content from this blog be used or interpreted as a recommendation of a trade or investment in Provectus Biopharmaceuticals, Inc. Trading and investing can be hazardous to your wealth, health or both. Any investment decision must, in all cases and without exception, be made by the reader or by his or her registered investment advisor. This blog is only and strictly for educational and informational purposes. The Author may have a position in Provectus Biopharmaceuticals, Inc. at any given time that is not disclosed at the time of publication. All opinions expressed by the Author are subject to change without notice. You, the reader, should always obtain current information and perform the appropriate due diligence before making any investment or trading decision. All efforts are made to ensure the information contained in the blog and/or a blog post is factual and accurate; however, the Author does not guarantee its accuracy under any circumstances.

♢ Note: Provectus' board of directors appointed the Author as a special adviser to the board in February 2017. See the blog's Disclosures page.

♢♢ Note: The Author and others entered into a securities transaction with Provectus. See the blog's Disclosures page.